Bone is not static tissue—it continuously remodels through a dance of osteoblasts building new matrix and osteoclasts clearing old material.
Bone is not static tissue—it continuously remodels through a dance of osteoblasts building new matrix and osteoclasts clearing old material. Osteoporosis occurs when remodelling becomes imbalanced, with too much removal and insufficient replacement, leaving a porous, fragile architecture vulnerable to fracture. Placental mesenchymal stem cells have attracted research interest because they can differentiate into osteoblasts, potentially helping restore bone-forming capacity. The mechanism appears to involve both direct cellular replacement of bone-building cells and the release of signalling molecules (cytokines) that shift the remodelling ratio back toward deposition. Early-stage trials are exploring whether cell therapy can slow or partially reverse the density loss that typically accelerates after oestrogen withdrawal in post-menopausal women, though robust efficacy data remain limited.
| Indikative Kosten · Bulgarien (EU) | €3,000–€8,000 |
|---|---|
| Globale Marktkostenfalle | €4,600–€7,350 (dvcstem.com) |
| Wichtigste untersuchte Zelltypen | MSZ aus Amnionmembran |
| Genehmigungsstatus | Experimentell |
| Registrierte Studien (ClinicalTrials.gov) | 14 · 2 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
A review of registered clinical trials identified 14 completed or published studies in osteoporosis using cell-based approaches, predominantly with placental MSCs, alongside 2 currently recruiting trials. Trial sizes have ranged from 20 to 120 participants. Several small studies report modest improvements in bone mineral density (typically 3–8% change from baseline over 12–24 months) and some reduction in fracture markers, though methodological heterogeneity limits direct comparison. No large, multi-centre, phase III efficacy trial has yet reported.
Depending on assessment, a Osteoporosis & Bone Health protocol may draw on:
Direct costs for cell therapy in osteoporosis clinics typically fall between €4,000 and €7,500 per treatment course, depending on cell type, expansion protocols, and delivery method. Imaging (DXA scans, sometimes CT) and baseline bone-metabolism blood panels add €500–1,200. Long-term monitoring costs, including serial imaging and repeated treatments if needed, can accumulate; many centres recommend follow-up assessment at 6 and 12 months, each adding investigation charges.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Osteoporosis & Bone Health cost-by-country breakdown, or compare the best countries for Osteoporosis & Bone Health →
Vor der Buchung prüfen: Sicherheit & Regulierung, das Erholungsklima, ob Sie geeignet sind, und welcher Zelltyp zu Osteoporosis & Bone Health passt.
Vollständiges Osteoporose und Knochengesundheit FAQ → · Osteoporose und Knochengesundheit Kostenaufschlüsselung →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Bin ich geeignet? · Welcher Zelltyp? · Types of clinics & best countries · Kostenrechner
Medizinisch geprüft vom Redaktionsteam von StemCellAtlas zusammen mit Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) der Partnerklinik Stem Plus (Sofia), gemäß ISSCR-, FDA- und EMA-Leitlinien. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung